Literature DB >> 1525602

Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.

V Méresse1, O Hartmann, G Vassal, E Benhamou, D Valteau-Couanet, L Brugieres, J Lemerle.   

Abstract

Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen. HVOD was diagnosed according to McDonald's clinical criteria. The incidence of HVOD was particularly high in this series (22%) compared with series with other conditioning regimens but the outcome was favorable in 26 patients (87%). Four deaths occurred (13%), one of which was HVOD related. The clinical presentation of HVOD was similar to that described in previous reports. Although statistical analysis failed to demonstrate any factors predictive of outcome, it did identify risk factors for the occurrence of HVOD: these were (1) a total dose of BU exceeding the standard 16 mg/kg dose; (2) the use of three as opposed to two alkylating agents; (3) the sequence of BU administration when given in the conditioning regimen containing three alkylating agents; and (4) concomitant ketoconazole therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525602

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  22 in total

1.  Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.

Authors:  Rish K Pai; Koen van Besien; John Hart; Andrew S Artz; Peter H O'Donnell
Journal:  Leuk Lymphoma       Date:  2012-03-13

Review 2.  Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. II: Deleterious consequences.

Authors:  T D Miale; S Sirithorn; S Ahmed
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

Review 3.  Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.

Authors:  J S McCune; P Jacobson; A Wiseman; O Militano
Journal:  Bone Marrow Transplant       Date:  2014-10-27       Impact factor: 5.483

Review 4.  Vascular liver diseases.

Authors:  Laurie D DeLeve
Journal:  Curr Gastroenterol Rep       Date:  2003-02

5.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Authors:  Andrew R Rezvani; Jeannine S McCune; Barry E Storer; Ami Batchelder; Aiko Kida; H Joachim Deeg; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

6.  Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.

Authors:  Joon Sup Song; Jong Jin Seo; Hyung Nam Moon; Thad Ghim; Ho Joon Im
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

7.  Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.

Authors:  Jeannine S McCune; K Scott Baker; David K Blough; Alan Gamis; Meagan J Bemer; Megan C Kelton-Rehkopf; Laura Winter; Jeffrey S Barrett
Journal:  J Clin Pharmacol       Date:  2013-01-24       Impact factor: 3.126

Review 8.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

9.  Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice.

Authors:  Jérôme Bouligand; Clémentine Richard; Dominique Valteau-Couanet; Cedric Orear; Lionel Mercier; Romain Kessari; Nicolas Simonnard; Fabienne Munier; Estelle Daudigeos-Dubus; Bassim Tou; Paule Opolon; Alain Deroussent; Angelo Paci; Gilles Vassal
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

10.  Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Authors:  G Vassal; S Koscielny; D Challine; D Valteau-Couanet; I Boland; A Deroussent; J Lemerle; A Gouyette; O Hartmann
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.